ChondroGene Collects Milestone Payment from Pfizer
Toronto-based ChondroGene last week reported a $1.58 million milestone payment from Pfizer in research on osteoarthritis markers. The payment is part of a two-year agreement begun in 2002 that includes an equity investment and regular quarterly payments that will total $7.5 million, exclusive of milestones and royalties. The company has created a human-cartilage-specific microarray, the ChondroChip.
PamGene Spins Off Check-Points
Netherlands-based PamGene International said last week that it would spin off its Check-Points business unit. The spinoff will commercialize PamGene’s 5D-Pulse flow-through microarray technology with a focus on food and water quality testing for micro organisms, as well as applications in the fermentation industry. PamGene will continue to focus its efforts on micro-arrays in the drug development process.
Aclara Biosciences In Supply Deal With Lawrence Livermore National Lab
Aclara Biosciences of Mountain View, Calif., last week announced that it will supply its eTag assay system to Lawrence Livermore National Lab for the development of detection systems for biological agents. The company will provide reagent products, software, and services. Financial details of the agreement were not provided.
Integrated Nano-Technologies Acquires Technion Patents
Integrated Nano-Technologies of Rochester, NY, last week announced the acquisition of a set of patents from Technion, the Israel Institute of Technology, which it intends to use to commercialize an electronic DNA detection system. The patents cover the metallization of DNA and will be used as part of the firm’s BioDetect system, a chip-based portable rapid testing device that will test for biological pathogens. The device is expected to be available by the end of the year, the company said in a statement. Financial details of the transaction were not available.
Paradigm Gets Nasdaq Extension Compliance
Nasdaq has granted Paradigm Genetics of Research Triangle Park, NC, a three-month extension in its bid to meet minimum requirements for listing on the exchange’s national market.
Paradigm, a biotech company that recently announced a microarray service business, was notified in January that it would be delisted from the exchange unless it could reach the market’s minimum $1 share price. The company appealed the decision.
Nasdaq recently changed its pricing rules, extending the compliance period from 90 to 180 days, with the possibility of an additional 180-day period, subject to approval by the Securities and Exchange Commission.
Molecular Probes Licenses To LightUp
Molecular Probes of Eugene, Ore., said last week that it will license its technology to LightUp Technol-ogies of Huddinge, Sweden. Financial details were not provided. Molecular provides fluorescence-based stains that LightUp will include in its DNA detection probes, which are expected to launch in the second quarter, the company said.
EraGen and Third Wave Settle
Third Wave Technologies and EraGen Biosciences last week announced the settlement of a patent infringement lawsuit filed by Third Wave.
EraGen did not admit infringement but will stop the development and sale of Gene Code products, version 1.0, 1.2, and 1.3, and will not use invasive cleavage structure, the technology in question in the settled suit, the financial terms of which were not disclosed.
CombiMatrix Sells Synthesizer to Keio University
The Japanese subsidiary of CombiMatrix has sold a DNA microarray synthesizer to the department of molecular biology of Keio University School of Medicine in Tokyo. The company last week made a similar announcement of a sale to Nihon Gene Research Laboratory (NGRL) in Sendai, Japan.
NimbleGen Systems Closes $12.5 M Series D
NimbleGen Systems of Madison, Wisc., announced Tuesday that it has closed series D financing of $12.5 million. The round was led by Schott Nexterion of Mainz, Germany, the life science division of the Schott Group. Also participating were previous investors in the company including Skyline Ventures, Venture Investors, Baird Venture Partners, Tactics II Investments, the State of Wisconsin Investment Board, and the Wisconsin Alumni Research Foundation, the company said. NimbleGen has taken in some $32.5 million in total investment since it was established in 2000.